On November 22, 2017 the Federal Court issued a judgment granting Apotex's motion under s. 6(5)(b) of the PMNOC Regulations: Bristol-Myers Squibb et al v Apotex Inc et al2017 FC 1061. As a result, the Court granted an order dismissing the underlying application in respect of Apotex's proposed generic aripiprazole product (Bristol-Myers Squibb and Otsuka's ABILIFY). The decision is under appeal.